Literature DB >> 24038838

Postdilatation for treatment of perivalvular aortic regurgitation after transcatheter aortic valve implantation.

Garikoitz Lasa1, Koldo Gaviria, Juan C Sanmartín, Miren Telleria, Mariano Larman.   

Abstract

OBJECTIVES: The study is made to describe the efficacy and safety of balloon postdilatation (BPD) for the treatment of residual aortic regurgitation (RAoR) after transcatheter aortic valve implantation (TAVI). METHODS AND
RESULTS: A single-center observational study is made with 157 consecutive patients accepted to TAVI. The patients were divided into two groups (no BPD-period and BPD-period). Before BPD, RAoR ≥ 2 was seen in 25% of the patients in group 1 and in 29% of the patients in group 2 (P ≥ 0.593). BPD was carried out in 95% (n = 21) of the patients in group 2 with RAoR ≥ 2. Regurgitation improved one grade in 68% of the cases (n = 15), 2 grades in 14% (n = 3), and remained without change in 18% (n = 4). RAoR < 2 was achieved in 91% (n = 73) of the patients in group 2 versus 75% (n = 58) in group 1 (RR = 0.35, 95% CI 0.16-0.80, P = 0.013). We recorded no aortic ring ruptures, damage to the device or displacements. Slight central regurgitation not present before BPD was registered in one case.
CONCLUSIONS: BPD offers a very good safety profile and reduces RAoR in a large percentage of cases. BPD should be considered for the treatment of moderate to severe RAoR following TAVI.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  TAVI; aortic valve regurgitation; aortic valve stenosis; balloon dilatation

Mesh:

Year:  2013        PMID: 24038838     DOI: 10.1002/ccd.25173

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  1 in total

1.  How to adapt the implantation technique for the new SAPIEN 3 transcatheter heart valve design.

Authors:  Gerhard Schymik; Holger Schröfel; Martin Heimeshoff; Armin Luik; Martin Thoenes; Lazar Mandinov
Journal:  J Interv Cardiol       Date:  2014-12-12       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.